Purpura fulminans

Summary

Purpura fulminans (MONDO:0000809) is a disease and 1 clinical trial. A subtype of disseminated intravascular coagulation — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	purpura fulminans
Mondo ID	MONDO:0000809
MeSH	D055665
DOID	DOID:0060538
ICD-11	1293848111
SNOMED CT	13507004
UMLS	C0085650
MedGen	88448
GARD	0022830
Is cancer (heuristic)	no

Also known as: fibrinolytic purpura

Disease family

This is a subtype of disseminated intravascular coagulation. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood coagulation disease › thrombophilia › disseminated intravascular coagulation › purpura fulminans

Related subtypes (1): disseminated intravascular coagulation in newborn

Subtypes (1): acquired purpura fulminans

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Protein C Concentrate (Human)	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03216577	Not specified	COMPLETED	Outcomes of Purpura FULminans in Adults - The hOPeFUL Study